A fusion between the pCloDF13-derived bacteriocin release protein and ,-1actamase was constructed to investigate the subceliular localization and posttranslational modification of the bacteriocin release protein in Escherichia coli. The signal sequence and 25 of the 28 amino acid residues of the mature bacteriocin release protein were fused to the mature portion of 4-lactamase. The hybrid protein (Mr, 31, 588) was expressed in minicells and whole cells and possessed full ,-lactamase activity. Immunoblotting of subceliular fractions revealed that the hybrid protein is present in both the cytoplasmic and outer membranes of E. coli. Radioastive labeling experiments in the presence or absence of globomycin showed that the hybrid protein is modified with a diglyceride and fatt acids and is processed by signal peptidase II, as is the murein lipoprotein. The results indicated that the pCloDF13-encoded bacteriocin release protein is a lipoprotein which is associated with both membranes of E. coli cells.
Bacteriocins are plasmid-encoded antibiotic proteins which are produced and released by bacteriocinogenic bacterial strains (17) . The release of bacteriocins in Escherichia coli is dependent on the expression of the gene encoding the so-called bacteriocin release protein (BRP). This gene is located in the various bacteriocin operons downstream from the inducible bacteriocin promoter and the bacteriocin structural gene. Induction of bacteriocin operons by activation of the host cell SOS response not only results in increased synthesis and release of bacteriocin, but also, in some instances, in lysis of host cells (7, 30) . The elevated level of BRP gene expression is primarily responsible for the observed lysis (19a, 32) .
The BRPs encoded by pColEl (kil product), pColE2-P9 (celB product), pColE3-CA38 (hic product), pColA-CA31 (cal product), and pCloDF13 (gene H product) havfe been sequenced and were found to share considerable sequence homology (3, 6, 7, 12, 26, 40) . Furthermore, the BRPs seem to be functionally interchangeable (31) . In contrast to their respective bacteriocins, the BRPs are synthesized as precursor molecules with an amino-terminal signal sequence and, like the murein lipoprotein, contain the consensus tetrapeptide which constitutes the recognition site for modification and processing enzymes (42) . All mature BRPs, except for the pColA-CA31-encoded BRP, have been localized in the cell envelopes of induced cells (6, 12, 15) . The colicin A release protein might be excreted into the medium together with colicin A (3). Subcellular localization studies in E. coti minicells showed that the pCloDF13-encoded BRP is present in both the cytoplasmic and outer membranes, but the majority (about 75%) was found in the outer membrane (28) .
The mode of action of the BRPs is still poorly understood. Recent experiments have indicated that induction of BRP synthesis results in activation of detergent-resistant phospholipase A, which in turn might cause local permeabiliza-* Corresponding author. tion of the outer membrane by the accumulation of lysophosphatidylethanolamine (20, 33) . It has been proposed that bacteriocin molecules use these permeabilization zones for their release in a semispecific manner and that strong induction of phospholipase A results in lysis of cells (7) . Translocation of bacteriocin across the cytoplasmic membrane is also dependent on BRP gene expression, but the mechanism is unknown.
We are investigating the processing, posttranslational modification, subcellular localization, and functioning of the pCloDF13-encoded BRP. Research on this polypeptide is difficult because of its low molecular mass, about 2,900 daltons for the mature protein, and the inability to detect the polypeptide in whole cells. To circumvent these problems, we constructed a hybrid gene containing the almost complete pCloDF13 BRP gene at its 5' end and a portion of the bla gene encoding mature P-lactamase at its 3' end. Experiments are presented here that indicate that the hybrid gene product is modified with a diglyceride and fatty acids, processed by the signal peptidase also involved in processing of the murein lipoprotein (SPase II), and located in both the cytoplasmic and outer membranes of E. coli. The implications of these results for the functioning of the BRP are discussed.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial strains used in this study were E. coli N3406 (38) and E. coli DS410 (9) . Plasmid pTG2 (16) was used as the cloning vector. The pCloDF13 derivative plasmid pEV67 has been described previously (12) . M9 minimal medium (22) (41) . Spheroplasts were collected by centrifugation, and the supematant was taken as the periplasmic fraction. Subsequently, the spheroplasts were broken by short periods of sonication, and the cytoplasmic and outer membranes (total membrane fraction) were collected by centrifugation (19) ; the supernatant fraction was taken as the cytoplasmic fraction. The total membrane fractions were treated with the detergents Triton X-100 and sodium lauroyl sarcosinate (Sarkosyl) as described elsewhere (5, 10) . Cytoplasmic and outer membranes were separated by isopycnic sucrose density gradient centrifupation as described by Osbom et al. (27) . Proteins present in periplasmic and cytoplasmic fractions were concentrated by trichloroacetic acid precipitation and washed with acetone before SDS-polyacrylamide gel electrophoresis and immunoblotting. ,B-Lactamase activity in the various fractions was assayed spectrophotometrically as described previously (25) . As controls, the activities of ,-galactosidase (22) and alkaline phosphatase (2) were measured as cytoplasmic and periplasmic markers, respectively.
Immunocytochemical labeling on cryosections. Immunocytochemical labeling with protein A-gold complexes on ultrathin cryosections of E. coli cells was carried out as described previously (36) .
Labeling experiments. Isolation and labeling of minicells with [35S]methionine, as well as the analysis of labeled polypeptides by SDS-polyacrylamide gel electrophoresis and autoradiography, were carried out as described by Mooi et al. (23) . Proteolytic processing in minicells was inhibited by the addition of 8.5% (vol/vol) ethanol (29 (1, 127 Ci/nmol) at 20 ,uCi/ml for 2 min. When necessary, globomycin dissolved in dimethyl sulfoxide (10 mg/ml) was added to the cultures to a final concentration of 100 jig/ml 30 min before labeling. Labeling was stopped by the addition of trichloroacetic acid to a final concentration of 10%. Precipitates were collected by centrifugation, washed with acetone and chloroform-methanol (2:1, vol/vol), dried, and dissolved in 1% SDS in 50 mM Tris hydrochloride buffer (pH 8.0) by heating at 100°C for 4 min. Subsequently, immunoprecipitations were carried out as described by Hayashi and Wu (13) with an antiserum against P-lactamase, and samples were analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography.
RESULTS BRP-j-lactamase hybrid gene construction. Plasmid pTG2 was used as the cloning vector for the construction of a hybrid gene encoding the amino4terminal signal sequence and a large portion of the pCloDF13-encoded BRP fused to the mature portion of 3-lactamase. Plasmid pTG2 is a pBR322 derivative in which the nucleotide sequence encoding the amino-terminal signal sequence of the RTEM ,Blactamase is flanked at its 5' end by a unique EcoRI site and at its 3' end by a unique BstEII site. This DNA fragment of pTG2 was removed and replaced by a DNA fragment encoding the BRP signal sequence and 25 of the 28 amino acid residues of mature BRP. The latter DNA fragment was derived from the pCloDF13 derivative plasmid pEV67 and was cloned into pTG2 using a shotgun cloning procedure. The strategy used for the construction of the hybrid gene is shown in Fig. 1A . Cells of E. coli N3406 were transformed with the constructed plasmids, and transformants were selected for ampicillin resistance, assuming that the BRP portion would be able to direct the BRP-13-lactamase hybrid protein into the periplasmic space without affecting the enzymatic functioning of ,-lactamase. Cells harboring deletion mutants of pTG2 lacking the P-lactamase signal se, quence accumulate P-lactamase in the cytoplasm and are sensitive to ampicillin (16) .
Of 14 ampicillin-resistant transformants, 2 harbored a plasmid of the expected size, expressed a protein which migrated more slowly than did P-lactamase on an SDSpolyacrylamide gel, and reacted with antiserum against ,B-lactamase in an immunoblotting experiment (data not shown). DNA sequence analysis of the small XmnI DNA fragment of the selected plasmids showed that the pEV67-derived DNA fragment was inserted in the correct orientation and reading frame (Fig. 1B) . Unexpectedly, in both plasmids the SmaI-FnuDII insert was preceded by the small FnuDII fragment containing terminator T2 of the cloacin operon in the orientation opposite to that of the bla promoter (Fig. 1A) . Several attempts to remove this additional terminator, T2, by subcloning the hybrid gene in an expression vector downstream of a strong, controllable promoter were not successful. These results strongly suggested that a high level of expression of the hybrid gene is deleterious to the cells.
One of the constructed plasmids, designated pJL12, was selected for further studies.
Detection and subcellular localization of the hybrid protein. The expression of the hybrid gene was analyzed with E. coli minicells (Fig. 2) . Two protein bands with apparent molecular weights of 32,500 and 34,000, respectively, were detected in minicells harboring pJL12. These bands were identified as the hybrid protein and its precursor. The apparent molecular weights of these bands were in good agreement with the calculated molecular weights of 31,588 and 34,171, respectively. The processing of the precursor of the hybrid protein could be completely inhibited by the addition of 8.5% ethanol to the label mixture. Control minicells harboring pTG2 expressed P-lactamase (molecular weight, 27,895) and its precursor (molecular weight, 31,502) ( Fig. 2; 16 ). The processing of this precursor was also completely hampered by the addition of 8.5% ethanol. Although the calculated molecular weights of the I3o lactamase precursor and the mature hybrid protein hardly differ, the latter protein clearly migrated more slowly, suggesting a possible modification of the hybrid protein. In some experiments a double band was detected at the position of the hybrid protein precursor, suggesting incomplete modification (data not shown).
The P-lactamase activity and subcellular localization of the hybrid protein were studied with whole E. coli cells. The 50% lethal dose of ampicillin for cells harboring pJL12 was four times lower than that for cells harboring pTG2. Radioactive labeling experiments revealed that this difference was due to a four-times-lower expression of the hybrid gene, rather than to a loss in specific ,-lactamase activity (data not orientation opposite to that of the promoter of P-lactamase. shown). Immunoblotting of subcellular fractions showed that the hybrid protein was located mainly in the total membrane fraction (Fig. 3) . Only minor amounts were found in the periplasmic and cytoplasmic fractions, and the protein could not be detected in the culture supernatant fraction. Most of the hybrid protein was solubilized when the total membrane fraction was treated with either Triton X-100 or Sarkosyl at room temperature, which suggested that the hybrid protein was not an integral outer membrane protein.
The total membrane fraction was also separated into cytoplasmic and outer membrane fractions, and the ,B-lactamase activity was determined. About 70% of the total activity was found in association with the outer membranes, and the remainder was found in the cytoplasmic membrane fraction.
To verify the localization of the hybrid protein, attempts were made to localize the hybrid protein in whole cells by using immunoelectron microscopy. Several different technical procedures were used, .but unfortunately, the hybrid protein could not be localized properly because of its low abundance.
Posttranslational modification of the BRP--lactamase hybrid protein. The antibiotic globomycin is a specific inhibitor of the signal peptidase SPase II, which specifically cleaves lipid-modified prolipoproteins (8, 14) . To obtain information on the possible lipoprotein nature of the pCloDF13-encoded BRP, the effect of globomycin on the processing of the precursor of the BRP-1-lactamase hybrid protein was studied (Fig. 4) . Cells of E. coli N3406 harboring pJL12 accumulated the precursor of the hybrid protein when they were treated with globomycin before being labeled with [35S]methionine. In the absence of globomycin, the mature fornm of the hybrid protein, as well as its precursor, was detected on the gel. This showed that the processing of the precursor of the hybrid protein was not complete in cells in the absence of inhibitor, probably because of the short labeling period. Globomycin did not affect the expression of ,B-lactamase or the processing of its precursor ( Fig. 4; 24) . D) or without (all other lanes) the addition of globomycin (100 ,ug/ml) 30 min before labeling. The labeled polypeptides were itnmunoprecipitated with an antiserum directed against ,B-lactamase and subjected to SDS-polyacrylamide gel electrophoresis followed by autoradiography. globomycin in minicells was studied (Fig. 2) . These results indicated that the precursor of the hybrid protein is processed by SPase II and is, consequently, a prolipoprotein.
To obtain further evidence that the BRP is a lipid-modified protein, the incorporation of [3H]glycerol and [3H]palmitate into the hybrid protein was studied (Fig. 4) and the mature portion of P-lactamase. Furthermore, processing of the BRP signal peptide from the hybrid protein precursor could be inhibited by globomycin. RTEM ,3-lactamase itself, encoded by pTG2, could not be labeled with radioactive lipid precursors, and the processing of its precursor could not be inhibited by globomycin, which is in agreement with results described previously (24) .
Subcellular localization experiments revealed that the mature hybrid protein is located in both the cytoplasmic and outer membranes of E. coli cells. However, about 75% of the protein was found in the outer membrane. This finding corresponds well with the localization of the pCIoDF13-encoded BRP in E. coli minicells (28) . Apparently, the cloned BRP portion is capable of directing P-lactamase, deprived of its own signal peptide, to the cell envelope and of anchoring the hybrid protein in the membranes. RTEM P-lactamase itself is located in the periplasm. The fact that the hybrid protein is fully active against ampicillin suggests that the ,-lactamase portion of the hybrid protein protrudes into the periplasm and is in the correct conformation for catalytic activity. It is conceivable that the association of the hybrid protein with the outer membranes is due to the presence of the lipid moiety in the BRP portion of the hybrid protein, as is the case with Braun's lipoprotein (4) . The nature of the association of the hybrid protein to the inner membranes is unknown. Possibly, information within the structure of the mature portion of the BRP is involved in this association, or these hybrid proteins are not yet completely modified and processed and are therefore still bound to the cytoplasmic membranes.
Ghrayeb and Inouye (11) constructed a fusion in which the signal sequence plus nine amino acids of the mature portion of the outer membrane lipoprotein were fused to the mature portion of the normally periplasmic P-lactamase. This hybrid protein was localized exclusively in the outer membrane of E. coli cells, and the P-lactamase portion of the hybrid protein was fully active. Assuming that the posttranslational modifications of the BRP and the lipoprotein are identical, the difference in the localization of the two hybrid proteins must be explained by the difference in the primary structures of the BRP and the murein lipoprotein.
All known BRPs possess strong sequence homology. Thus, posttranslational modification of BRPs with a glyceride and fatty acids might be a general phenomenon. Yamada et al. (43) described the inhibition of release of colicin El by globomycin. They concluded that colicin El, which contains an internal signallike sequence, and lipoprotein use a common site for their translocation across the cytoplasmic membrane. However, our results suggest that globomycin inhibits the proper modification and processing of the pColEl-encoded BRP, which is required for colicin El export (34, 44) . Excretion experiments (Oudega, unpublished data) also showed that suboptimal concentrations of globomycin which had no direct effect on cell lysis inhibited the release of cloacin DF13 by induced cells and thus the functioning of the BRP.
Vernet et al. (39) constructed a fusion between the almost complete BRP of pColE3-CA38 (hic gene product) and human proinsulin. Attempts to characterize the hybrid protein were not successful, and cell lysis was observed after 60 to 90 min of induction. Results described in this paper strongly suggest that a higher level of expression of the BRP-1-lactamase hybrid protein than that observed in strain N3406 harboring pJL12 results in cell death. Possibly, the BRP part of both hybrid proteins is responsible for this deleterious effect.
The experiments described in this paper indicate that the targeting and therefore the functioning of the pCloDF13-encoded BRP is aided by lipid moieties. Currently, we are constructing, by site-directed in vitro mutagenesis, several BRP mutants to further investigate the role of posttranslational lipid modification in the localization and functioning of the BRP. Analysis of a constructed mutant showed that the amino-terminal cysteine residue of the mature BRP is essential, since a replacement of this cysteine by a glycine residue resulted in a nonfunctional release protein.
